(4S,5R)-2,4-Diphenyl-4,5-dihydrooxazole-5-carboxylic acid

We are (4S,5R)-2,4-Diphenyl-4,5-dihydrooxazole-5-carboxylic acid CAS:158722-22-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(4S,5R)-2,4-Diphenyl-4,5-dihydrooxazole-5-carboxylic acid
CAS.NO:158722-22-6
Synonyms:(4S,5R)-2,4-Diphenyl-4,5-dihydro-1,3-oxazole-5-carboxylic acid
Molecular Formula:C16H13NO3
Molecular Weight:267.27900
 
Specification:
Appearance:White powder
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:An intermediate in the preparation of potent anticancer drug Paclitaxel

(4S,5R)-2,4-Diphenyl-4,5-dihydrooxazole-5-carboxylic acid


Related News: Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%.5-Bromo-2-Hydroxy-3-Picoline CAS:89488-30-2 Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs.2,6-dicloropurina-9-b-D-ribósido CAS:13276-52-3 Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs.5434-20-8 Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs.Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added “The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.

Related Products
Product Name
2-(2-chlorophenyl)acetic acid View Details
4-fluoroaniline View Details
1,3-Bis(2,4-Diaminophenoxy)Propane 4HCl View Details
4-(2-Methoxyethyl)phenol manufacturer 3,4-Diethoxyaniline manufacturer 2′-deoxyadenosine manufacturer 3-Chloro-4-Iodopyridine manufacturer 1,8-Dibromooctane manufacturer